Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBIT: 2016-2024

Historic EBIT for Dianthus Therapeutics (DNTH) over the last 7 years, with Dec 2024 value amounting to -$101.9 million.

  • Dianthus Therapeutics' EBIT fell 34.74% to -$40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.3 million, marking a year-over-year decrease of 69.24%. This contributed to the annual value of -$101.9 million for FY2024, which is 111.45% down from last year.
  • According to the latest figures from FY2024, Dianthus Therapeutics' EBIT is -$101.9 million, which was down 111.45% from -$48.2 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' EBIT ranged from a high of -$29.7 million in FY2022 and a low of -$101.9 million during FY2024.
  • Over the past 3 years, Dianthus Therapeutics' median EBIT value was -$48.2 million (recorded in 2023), while the average stood at -$59.9 million.
  • Data for Dianthus Therapeutics' EBIT shows a maximum YoY plummeted of 111.45% (in 2024) over the last 5 years.
  • Over the past 3 years, Dianthus Therapeutics' EBIT (Yearly) stood at -$29.7 million in 2022, then tumbled by 62.17% to -$48.2 million in 2023, then slumped by 111.45% to -$101.9 million in 2024.